 
     
    Species level identification of 
microorganisms is vital in combating the vast range of pathogens that 
infect humans. Bacteria, yeast and mycobacteria, whether clinically 
common or rare, can cause serious harm when not identified and treated 
quickly. Increasingly prevalent conditions, such as sepsis or multi-drug
 resistant (MDR) microorganism infections, pose a serious threat to 
hospitals and wider public health, requiring rapid, automated microbial 
identification and resistance testing solutions for the entire clinical 
workflow.
In parallel, effective hygiene management – especially in hospitals – is key to prevent healthcare associated infections as effectively as possible.
Bruker’s MALDI Biotyper®
 system has become the method of choice for routine microorganism 
identification in clinical laboratories worldwide. Based on 
Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight mass 
spectrometry (MALDI-TOF MS) technology, this microbial identification 
system is easy-to-use, fast, robust, high-throughput, cost-effective and
 highly efficient. Molecular diagnostics are another rapid solution for 
clinical microbiology, enabling real-time results in a culture-free 
workflow, for example in the case of fungal infections. Bruker’s 
expertise in antimicrobial susceptibility testing (AST) and mycobacteria
 identification provides a complete solution, continuously innovating to
 address today’s global diseases.